Preparation and use of molecular site targeted and activated kinase inhibitor
AssigneeYafei Shanghai Biology Medicine Science & Technology Co. Ltd.
InventorsYuan Liu, Cheng Liu, Haiyang Wang
Life of this patent
Estimating the term…
Abstract
Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is —NH-phenyl-CH2-O—; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., —OC(O)—.
Claims6
A compound represented by the following formula A or a pharmaceutically acceptable salt thereof:
- Lacto-XAN-PABC-Z (Formula A)
- wherein,
- X is alanine, proline or threonine;
- A is alanine;
- N is asparagine;
- PABC is —NH-phenyl-CH2—O—;
- Z is a drug molecule selected from the group consisting of doxorubicin, darafinib, dovetinib, motesanib and a sorafenib derivative represented by the following formula B:
- wherein R is H or halogen;
- Lacto is lactobionic acid residue;
- wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond;
- PABC is bonded to Z by an ester group, namely —OC(O)—.
Dependencies are inferred from the claim text.